GoAI
Get started
Hongli Group Inc. logo

Hongli Group Inc.

HLP

NASDAQBasic MaterialsSteel

Open in GoAI

Regular session

$1.25

+$0.07 · +5.93%

Aug 24, 1:23 PM ET

HLP company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

74

Undervalued

Momentum

51

Neutral

Sentiment

55

Mixed

Risk resilience

45

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Hongli Group Inc., through its affiliated entities, specializes in the engineering, tailoring, production, and distribution of cold roll-formed steel profiles. These precision components are utilized in a variety of machinery and equipment, with a market reach that extends across the People's Republic of China, South Korea, Japan, the United States, and Sweden. The company's products cater to essential sectors such as mining and excavation, construction, agriculture, and transportation. Established in 2021, the firm's corporate headquarters are situated in Weifang, China. Hongli Group Inc. operates as a subsidiary of Hongli Development Limited.

Industry
Steel
Sector
Basic Materials
Headquarters
CN
CEO
Jie Liu
Listed since
Mar 29, 2023
Employees
167

Market position

Day range

Current $1.25

52-week range

Current $1.25

Open
$1.19
Previous close
$1.18
Volume
9.92K
0.01× average
Average volume
1.4M
Average daily volume
Market cap
93.42M USD
Beta
0.49
Market reference 1
50-day average
$0.9698
+28.90% above average
200-day average
$1.0192
+22.65% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
86.01M USD
P/E (TTM)
47.17×
P/B (TTM)
1.58×
P/S (TTM)
4.77×
EV / EBITDA
26.51×
Earnings yield
2.54%
Free cash flow yield
0.87%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
32.54%
Operating margin
12.41%
Net margin
9.91%
Return on equity
3.36%
Return on assets
2.69%
Return on invested capital
3.14%

Financial health

Debt / equity
0.2×
Current ratio
1.12×
Altman Z-score
4.49
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends40%21%1%-18%Gross margin, FY2021: 35.25%Gross margin, FY2022: 34.55%Gross margin, FY2023: 32.79%Gross margin, FY2024: 32.04%Gross margin, FY2025: 32.54%Operating margin, FY2021: 18.12%Operating margin, FY2022: 14.40%Operating margin, FY2023: 6.38%Operating margin, FY2024: -11.22%Operating margin, FY2025: 12.41%Net margin, FY2021: 14.75%Net margin, FY2022: 14.46%Net margin, FY2023: 5.41%Net margin, FY2024: -13.34%Net margin, FY2025: 9.91%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 35.25%. Gross margin FY2022 34.55%. Gross margin FY2023 32.79%. Gross margin FY2024 32.04%. Gross margin FY2025 32.54%. Operating margin FY2021 18.12%. Operating margin FY2022 14.40%. Operating margin FY2023 6.38%. Operating margin FY2024 -11.22%. Operating margin FY2025 12.41%. Net margin FY2021 14.75%. Net margin FY2022 14.46%. Net margin FY2023 5.41%. Net margin FY2024 -13.34%. Net margin FY2025 9.91%.

Income trends

Revenue

19.6M USD+38.96%

Operating income

2.43M USD+4.02M USD

Net income

1.94M USD+3.82M USD
Income trends across reported periods24.07M USD14.63M USD5.2M USD−4.24M USDRevenue, FY2021: 21.71M USDRevenue, FY2022: 20.28M USDRevenue, FY2023: 16M USDRevenue, FY2024: 14.11M USDRevenue, FY2025: 19.6M USDOperating income, FY2021: 3.94M USDOperating income, FY2022: 2.92M USDOperating income, FY2023: 1.02M USDOperating income, FY2024: −1.58M USDOperating income, FY2025: 2.43M USDNet income, FY2021: 3.2M USDNet income, FY2022: 2.93M USDNet income, FY2023: 864.72K USDNet income, FY2024: −1.88M USDNet income, FY2025: 1.94M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 21.71M USD. Revenue FY2022 20.28M USD. Revenue FY2023 16M USD. Revenue FY2024 14.11M USD. Revenue FY2025 19.6M USD. Operating income FY2021 3.94M USD. Operating income FY2022 2.92M USD. Operating income FY2023 1.02M USD. Operating income FY2024 −1.58M USD. Operating income FY2025 2.43M USD. Net income FY2021 3.2M USD. Net income FY2022 2.93M USD. Net income FY2023 864.72K USD. Net income FY2024 −1.88M USD. Net income FY2025 1.94M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue19.6M USD14.11M USD16M USD20.28M USD21.71M USD
Cost of goods sold13.22M USD9.59M USD10.75M USD13.27M USD14.06M USD
Gross profit6.38M USD4.52M USD5.25M USD7.01M USD7.65M USD
Research and development994.5K USD818.32K USD962.96K USD1.41M USD1.47M USD
Selling, general, and administrative2.95M USD6.1M USD3.14M USD2.59M USD2.18M USD
Operating expenses3.95M USD6.1M USD4.23M USD4.09M USD3.72M USD
Interest expense469.71K USD466.39K USD643K USD244.01K USD537.52K USD
Depreciation and amortization811.21K USD943.05K USD1.05M USD655.41K USD701.79K USD
Operating income2.43M USD−1.58M USD1.02M USD2.92M USD3.94M USD
Net income1.94M USD−1.88M USD864.72K USD2.93M USD3.2M USD

Company facts updated Aug 24, 2026.

HLP news

seekingalpha.com

Helus Pharma: An Undervalued Psychedelic Platform Approaching A Major Catalyst

Helus Pharma has built a proprietary psychedelic pipeline that currently spans MDD and GAD. The company has two clinical-stage assets and a broader serotonergic discovery platform. Early HLP003 (oral psilocin) and HLP004…

Read source
prnewswire.com

Hongli Group Inc. Announces Compliance with Nasdaq Minimum Bid Price Requirement

WEIFANG, China, Aug. 12, 2026 /PRNewswire/ -- Hongli Group Inc. (the "Company") (Nasdaq: HLP), a cold roll formed steel profile manufacturer, today announced that on August 7, 2026, it received a notification letter from…

Read source
globenewswire.com

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program Participant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability data APPROACH topline…

Read source
seekingalpha.com

Helus Pharma: APPROACHing Inflection: Pivotal Readout Sets Up Asymmetric Upside

I initiate coverage of Helus Pharma with a speculative Buy, citing an attractive high-risk/high-reward setup ahead of the pivotal Phase 3 APPROACH readout in Q4 2026. HELP's lead asset HLP003, an oral deuterated psilocin…

Read source
prnewswire.com

Hongli Group Inc. Receives Nasdaq Notice Regarding Minimum Bid Price Deficiency

WEIFANG, China, July 9, 2026 /PRNewswire/ -- Hongli Group Inc. (the "Company") (Nasdaq: HLP), a cold roll formed steel profile manufacturer, today announced that on July 2, 2026, it received a deficiency letter (the…

Read source
prnewswire.com

Hongli Group Inc. Entered into Strategic Non-Binding MOU with Sidus Energy Storage, Inc. to Explore Potential Advanced Battery Manufacturing Collaboration

Proposed Partnership Supports the Company's ongoing Strategic Shift Toward Clean Energy and Energy Storage Solutions WEIFANG, China, June 15, 2026 /PRNewswire/ -- Hongli Group Inc. (Nasdaq: HLP) (the "Company" or "Hongli…

Read source

HLP peers

Linde plc logo

LIN

Linde plc

$485.86

-0.35%

Steel Dynamics, Inc. logo

STLD

Steel Dynamics, Inc.

$230.22

+0.67%

Royal Gold, Inc. logo

RGLD

Royal Gold, Inc.

$260.55

+0.60%

Solstice Advanced Materials Inc. logo

SOLS

Solstice Advanced Materials Inc.

$55.8324

-0.58%

SSR Mining Inc. logo

SSRM

SSR Mining Inc.

$38.16

+1.03%

Aura Minerals logo

AUGO

Aura Minerals

$87.2202

-0.05%

Continue in GoAI

Research HLP

research.disclaimer